Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-07 07:30 |
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations i…
|
English | 40.7 KB | ||
| 2024-10-30 16:20 |
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting…
|
English | 13.9 KB | ||
| 2024-10-16 11:55 |
APONTIS PHARMA and Zentiva entered into partnership for future growth Zentiva …
|
English | 17.1 KB | ||
| 2024-10-16 11:50 |
APONTIS PHARMA and Zentiva enter into investment agreement Zentiva will launch…
|
English | 9.1 KB | ||
| 2024-09-13 00:00 |
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 377.6 KB | ||
| 2024-08-09 07:30 |
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in t…
|
English | 36.1 KB | ||
| 2024-08-09 00:00 |
Half-yearly financial statements 2024
|
English | 739.2 KB | ||
| 2024-06-27 07:30 |
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a…
|
English | 9.8 KB | ||
| 2024-06-04 07:30 |
APONTIS PHARMA continues to gear organization towards growth and internationali…
|
English | 10.0 KB | ||
| 2024-05-14 11:10 |
APONTIS PHARMA AG: Thomas Milz, buy
|
English | 7.6 KB | ||
| 2024-05-14 11:08 |
APONTIS PHARMA AG: be executive GmbH, buy
|
English | 7.9 KB | ||
| 2024-05-13 07:30 |
APONTIS PHARMA AG: Thomas Zimmermann, buy
|
English | 7.6 KB | ||
| 2024-05-08 07:30 |
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill…
|
English | 36.9 KB | ||
| 2024-04-05 10:17 |
APONTIS PHARMA enters five-year distribution and marketing agreement with Novar…
|
English | 9.0 KB | ||
| 2024-04-05 10:10 |
APONTIS PHARMA AG raises forecast after entering five-year distribution and mar…
|
English | 6.7 KB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
